nodes	percent_of_prediction	percent_of_DWPC	metapath
Dorzolamide—CA7—colon cancer	0.757	1	CbGaD
Dorzolamide—CA14—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0153	0.123	CbGpPWpGaD
Dorzolamide—CA5A—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0149	0.12	CbGpPWpGaD
Dorzolamide—CA6—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0149	0.12	CbGpPWpGaD
Dorzolamide—CA5B—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0139	0.112	CbGpPWpGaD
Dorzolamide—CA12—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0129	0.104	CbGpPWpGaD
Dorzolamide—CA4—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0103	0.083	CbGpPWpGaD
Dorzolamide—CA2—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00984	0.0796	CbGpPWpGaD
Dorzolamide—CA1—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00943	0.0763	CbGpPWpGaD
Dorzolamide—CA9—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00829	0.0671	CbGpPWpGaD
Dorzolamide—Brinzolamide—CA7—colon cancer	0.00709	1	CrCbGaD
Dorzolamide—CYP2C9—Capecitabine—colon cancer	0.00314	0.441	CbGbCtD
Dorzolamide—CA9—gall bladder—colon cancer	0.00233	0.116	CbGeAlD
Dorzolamide—CYP2C9—Fluorouracil—colon cancer	0.00186	0.262	CbGbCtD
Dorzolamide—CA7—renal system—colon cancer	0.00127	0.0636	CbGeAlD
Dorzolamide—CA5A—liver—colon cancer	0.00117	0.0584	CbGeAlD
Dorzolamide—CYP3A4—Irinotecan—colon cancer	0.00113	0.159	CbGbCtD
Dorzolamide—CA7—digestive system—colon cancer	0.00104	0.0522	CbGeAlD
Dorzolamide—CYP3A4—Vincristine—colon cancer	0.000987	0.139	CbGbCtD
Dorzolamide—CA9—digestive system—colon cancer	0.000918	0.0458	CbGeAlD
Dorzolamide—CA2—gall bladder—colon cancer	0.000885	0.0442	CbGeAlD
Dorzolamide—CA12—renal system—colon cancer	0.000828	0.0413	CbGeAlD
Dorzolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—colon cancer	0.000761	0.00615	CbGpPWpGaD
Dorzolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—colon cancer	0.00072	0.00583	CbGpPWpGaD
Dorzolamide—CA12—digestive system—colon cancer	0.000679	0.0339	CbGeAlD
Dorzolamide—CA1—renal system—colon cancer	0.000656	0.0327	CbGeAlD
Dorzolamide—CA14—liver—colon cancer	0.000648	0.0324	CbGeAlD
Dorzolamide—CA2—embryo—colon cancer	0.000561	0.028	CbGeAlD
Dorzolamide—CA1—lymphoid tissue—colon cancer	0.000544	0.0272	CbGeAlD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000544	0.0044	CbGpPWpGaD
Dorzolamide—CA1—digestive system—colon cancer	0.000538	0.0269	CbGeAlD
Dorzolamide—CA5B—vagina—colon cancer	0.000538	0.0269	CbGeAlD
Dorzolamide—CA4—renal system—colon cancer	0.000512	0.0256	CbGeAlD
Dorzolamide—CA1—bone marrow—colon cancer	0.000496	0.0248	CbGeAlD
Dorzolamide—CA2—epithelium—colon cancer	0.000458	0.0229	CbGeAlD
Dorzolamide—CA2—smooth muscle tissue—colon cancer	0.000441	0.022	CbGeAlD
Dorzolamide—CA2—renal system—colon cancer	0.000425	0.0212	CbGeAlD
Dorzolamide—CA4—digestive system—colon cancer	0.00042	0.021	CbGeAlD
Dorzolamide—CA1—liver—colon cancer	0.000401	0.02	CbGeAlD
Dorzolamide—CA4—bone marrow—colon cancer	0.000387	0.0194	CbGeAlD
Dorzolamide—CA2—lymphoid tissue—colon cancer	0.000353	0.0176	CbGeAlD
Dorzolamide—CA2—digestive system—colon cancer	0.000348	0.0174	CbGeAlD
Dorzolamide—CA5B—lymph node—colon cancer	0.000348	0.0174	CbGeAlD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000339	0.00275	CbGpPWpGaD
Dorzolamide—Myocardial infarction—Vincristine—colon cancer	0.000336	0.00395	CcSEcCtD
Dorzolamide—CA9—Cellular response to hypoxia—EP300—colon cancer	0.000336	0.00272	CbGpPWpGaD
Dorzolamide—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000333	0.00392	CcSEcCtD
Dorzolamide—Acute coronary syndrome—Irinotecan—colon cancer	0.000329	0.00387	CcSEcCtD
Dorzolamide—Sweating—Vincristine—colon cancer	0.000329	0.00387	CcSEcCtD
Dorzolamide—Myocardial infarction—Irinotecan—colon cancer	0.000327	0.00385	CcSEcCtD
Dorzolamide—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000327	0.00265	CbGpPWpGaD
Dorzolamide—CA2—bone marrow—colon cancer	0.000321	0.016	CbGeAlD
Dorzolamide—Eye pain—Capecitabine—colon cancer	0.000321	0.00378	CcSEcCtD
Dorzolamide—Sweating—Irinotecan—colon cancer	0.00032	0.00377	CcSEcCtD
Dorzolamide—CA9—Cellular response to hypoxia—VEGFA—colon cancer	0.000318	0.00257	CbGpPWpGaD
Dorzolamide—Acute coronary syndrome—Fluorouracil—colon cancer	0.000315	0.00371	CcSEcCtD
Dorzolamide—Myocardial infarction—Fluorouracil—colon cancer	0.000313	0.00369	CcSEcCtD
Dorzolamide—Libido decreased—Capecitabine—colon cancer	0.000313	0.00368	CcSEcCtD
Dorzolamide—Urinary tract infection—Fluorouracil—colon cancer	0.000311	0.00366	CcSEcCtD
Dorzolamide—Conjunctivitis—Fluorouracil—colon cancer	0.000311	0.00366	CcSEcCtD
Dorzolamide—CA14—Metabolism—CA7—colon cancer	0.00031	0.00251	CbGpPWpGaD
Dorzolamide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000309	0.0025	CbGpPWpGaD
Dorzolamide—Amnesia—Capecitabine—colon cancer	0.000309	0.00363	CcSEcCtD
Dorzolamide—CA2—vagina—colon cancer	0.000308	0.0154	CbGeAlD
Dorzolamide—Dermatitis exfoliative—Capecitabine—colon cancer	0.000307	0.00362	CcSEcCtD
Dorzolamide—CA1—lymph node—colon cancer	0.000307	0.0153	CbGeAlD
Dorzolamide—Hallucination—Vincristine—colon cancer	0.000306	0.0036	CcSEcCtD
Dorzolamide—Bradycardia—Irinotecan—colon cancer	0.000305	0.00359	CcSEcCtD
Dorzolamide—Respiratory failure—Methotrexate—colon cancer	0.000303	0.00356	CcSEcCtD
Dorzolamide—CA5A—Metabolism—CA7—colon cancer	0.000302	0.00245	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—CA7—colon cancer	0.000302	0.00245	CbGpPWpGaD
Dorzolamide—Epistaxis—Fluorouracil—colon cancer	0.000302	0.00355	CcSEcCtD
Dorzolamide—Sinusitis—Fluorouracil—colon cancer	0.0003	0.00353	CcSEcCtD
Dorzolamide—Agranulocytosis—Fluorouracil—colon cancer	0.000298	0.00351	CcSEcCtD
Dorzolamide—Cardiac failure—Capecitabine—colon cancer	0.000297	0.0035	CcSEcCtD
Dorzolamide—Cerebrovascular accident—Capecitabine—colon cancer	0.000296	0.00348	CcSEcCtD
Dorzolamide—CYP2C9—digestive system—colon cancer	0.000295	0.0147	CbGeAlD
Dorzolamide—Pain in extremity—Capecitabine—colon cancer	0.00029	0.00341	CcSEcCtD
Dorzolamide—Diplopia—Capecitabine—colon cancer	0.00029	0.00341	CcSEcCtD
Dorzolamide—Visual impairment—Irinotecan—colon cancer	0.000289	0.0034	CcSEcCtD
Dorzolamide—Disturbance in sexual arousal—Capecitabine—colon cancer	0.000288	0.00339	CcSEcCtD
Dorzolamide—Pharyngitis—Fluorouracil—colon cancer	0.000285	0.00335	CcSEcCtD
Dorzolamide—CA5B—Metabolism—CA7—colon cancer	0.000282	0.00228	CbGpPWpGaD
Dorzolamide—Cardiac arrest—Capecitabine—colon cancer	0.000276	0.00324	CcSEcCtD
Dorzolamide—Mood swings—Capecitabine—colon cancer	0.000275	0.00323	CcSEcCtD
Dorzolamide—CYP3A4—renal system—colon cancer	0.000274	0.0137	CbGeAlD
Dorzolamide—Alopecia—Vincristine—colon cancer	0.000272	0.0032	CcSEcCtD
Dorzolamide—Arrhythmia—Irinotecan—colon cancer	0.000268	0.00315	CcSEcCtD
Dorzolamide—Alopecia—Irinotecan—colon cancer	0.000265	0.00312	CcSEcCtD
Dorzolamide—Pulmonary oedema—Methotrexate—colon cancer	0.000265	0.00311	CcSEcCtD
Dorzolamide—CA12—Metabolism—CA7—colon cancer	0.000261	0.00211	CbGpPWpGaD
Dorzolamide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000261	0.00307	CcSEcCtD
Dorzolamide—CA2—liver—colon cancer	0.00026	0.013	CbGeAlD
Dorzolamide—Back pain—Vincristine—colon cancer	0.000259	0.00305	CcSEcCtD
Dorzolamide—Arrhythmia—Fluorouracil—colon cancer	0.000256	0.00302	CcSEcCtD
Dorzolamide—Alopecia—Fluorouracil—colon cancer	0.000254	0.00299	CcSEcCtD
Dorzolamide—Back pain—Irinotecan—colon cancer	0.000252	0.00297	CcSEcCtD
Dorzolamide—Influenza—Capecitabine—colon cancer	0.000251	0.00295	CcSEcCtD
Dorzolamide—Erythema—Fluorouracil—colon cancer	0.00025	0.00294	CcSEcCtD
Dorzolamide—Bronchospasm—Capecitabine—colon cancer	0.000247	0.0029	CcSEcCtD
Dorzolamide—Angina pectoris—Capecitabine—colon cancer	0.000244	0.00287	CcSEcCtD
Dorzolamide—Bronchitis—Capecitabine—colon cancer	0.000241	0.00284	CcSEcCtD
Dorzolamide—Vertigo—Vincristine—colon cancer	0.000241	0.00283	CcSEcCtD
Dorzolamide—CA4—lymph node—colon cancer	0.00024	0.012	CbGeAlD
Dorzolamide—Vision blurred—Fluorouracil—colon cancer	0.000236	0.00277	CcSEcCtD
Dorzolamide—Vertigo—Irinotecan—colon cancer	0.000234	0.00276	CcSEcCtD
Dorzolamide—Dysuria—Capecitabine—colon cancer	0.000234	0.00276	CcSEcCtD
Dorzolamide—Syncope—Irinotecan—colon cancer	0.000234	0.00275	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Capecitabine—colon cancer	0.000233	0.00274	CcSEcCtD
Dorzolamide—Hypertension—Vincristine—colon cancer	0.000231	0.00272	CcSEcCtD
Dorzolamide—Loss of consciousness—Irinotecan—colon cancer	0.000229	0.0027	CcSEcCtD
Dorzolamide—Dermatitis exfoliative—Methotrexate—colon cancer	0.000229	0.00269	CcSEcCtD
Dorzolamide—Visual disturbance—Methotrexate—colon cancer	0.000228	0.00268	CcSEcCtD
Dorzolamide—Cough—Irinotecan—colon cancer	0.000228	0.00268	CcSEcCtD
Dorzolamide—Weight decreased—Capecitabine—colon cancer	0.000227	0.00267	CcSEcCtD
Dorzolamide—Hyperglycaemia—Capecitabine—colon cancer	0.000226	0.00266	CcSEcCtD
Dorzolamide—Hypertension—Irinotecan—colon cancer	0.000225	0.00265	CcSEcCtD
Dorzolamide—CYP3A4—digestive system—colon cancer	0.000225	0.0112	CbGeAlD
Dorzolamide—Depression—Capecitabine—colon cancer	0.000223	0.00262	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000222	0.00261	CcSEcCtD
Dorzolamide—Acute coronary syndrome—Capecitabine—colon cancer	0.00022	0.00259	CcSEcCtD
Dorzolamide—Cerebrovascular accident—Methotrexate—colon cancer	0.00022	0.00259	CcSEcCtD
Dorzolamide—CYP2C9—liver—colon cancer	0.00022	0.011	CbGeAlD
Dorzolamide—Discomfort—Irinotecan—colon cancer	0.000219	0.00258	CcSEcCtD
Dorzolamide—Myocardial infarction—Capecitabine—colon cancer	0.000219	0.00258	CcSEcCtD
Dorzolamide—Oedema—Vincristine—colon cancer	0.000219	0.00257	CcSEcCtD
Dorzolamide—Anaphylactic shock—Vincristine—colon cancer	0.000219	0.00257	CcSEcCtD
Dorzolamide—Urinary tract infection—Capecitabine—colon cancer	0.000217	0.00256	CcSEcCtD
Dorzolamide—Conjunctivitis—Capecitabine—colon cancer	0.000217	0.00256	CcSEcCtD
Dorzolamide—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000216	0.00175	CbGpPWpGaD
Dorzolamide—Confusional state—Irinotecan—colon cancer	0.000215	0.00253	CcSEcCtD
Dorzolamide—Oedema—Irinotecan—colon cancer	0.000213	0.00251	CcSEcCtD
Dorzolamide—Anaphylactic shock—Irinotecan—colon cancer	0.000213	0.00251	CcSEcCtD
Dorzolamide—Chest pain—Fluorouracil—colon cancer	0.000213	0.0025	CcSEcCtD
Dorzolamide—Hyperhidrosis—Vincristine—colon cancer	0.000211	0.00249	CcSEcCtD
Dorzolamide—Epistaxis—Capecitabine—colon cancer	0.000211	0.00248	CcSEcCtD
Dorzolamide—Discomfort—Fluorouracil—colon cancer	0.00021	0.00247	CcSEcCtD
Dorzolamide—Shock—Irinotecan—colon cancer	0.00021	0.00247	CcSEcCtD
Dorzolamide—Agranulocytosis—Capecitabine—colon cancer	0.000209	0.00245	CcSEcCtD
Dorzolamide—CA4—Metabolism—CA7—colon cancer	0.000208	0.00169	CbGpPWpGaD
Dorzolamide—Anorexia—Vincristine—colon cancer	0.000208	0.00245	CcSEcCtD
Dorzolamide—Hyperhidrosis—Irinotecan—colon cancer	0.000206	0.00242	CcSEcCtD
Dorzolamide—Confusional state—Fluorouracil—colon cancer	0.000206	0.00242	CcSEcCtD
Dorzolamide—Mood swings—Methotrexate—colon cancer	0.000205	0.00241	CcSEcCtD
Dorzolamide—Hypotension—Vincristine—colon cancer	0.000204	0.0024	CcSEcCtD
Dorzolamide—Bradycardia—Capecitabine—colon cancer	0.000204	0.0024	CcSEcCtD
Dorzolamide—Anaphylactic shock—Fluorouracil—colon cancer	0.000204	0.0024	CcSEcCtD
Dorzolamide—Oedema—Fluorouracil—colon cancer	0.000204	0.0024	CcSEcCtD
Dorzolamide—Anorexia—Irinotecan—colon cancer	0.000203	0.00239	CcSEcCtD
Dorzolamide—CA2—Metabolism—CA7—colon cancer	0.0002	0.00162	CbGpPWpGaD
Dorzolamide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000199	0.00234	CcSEcCtD
Dorzolamide—Pharyngitis—Capecitabine—colon cancer	0.000199	0.00234	CcSEcCtD
Dorzolamide—CA2—lymph node—colon cancer	0.000199	0.00994	CbGeAlD
Dorzolamide—Hypotension—Irinotecan—colon cancer	0.000199	0.00234	CcSEcCtD
Dorzolamide—Insomnia—Vincristine—colon cancer	0.000198	0.00233	CcSEcCtD
Dorzolamide—Paraesthesia—Vincristine—colon cancer	0.000196	0.00231	CcSEcCtD
Dorzolamide—Anorexia—Fluorouracil—colon cancer	0.000194	0.00229	CcSEcCtD
Dorzolamide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000194	0.00229	CcSEcCtD
Dorzolamide—Visual impairment—Capecitabine—colon cancer	0.000193	0.00227	CcSEcCtD
Dorzolamide—Insomnia—Irinotecan—colon cancer	0.000193	0.00227	CcSEcCtD
Dorzolamide—CA1—Metabolism—CA7—colon cancer	0.000192	0.00155	CbGpPWpGaD
Dorzolamide—Paraesthesia—Irinotecan—colon cancer	0.000191	0.00225	CcSEcCtD
Dorzolamide—Hypotension—Fluorouracil—colon cancer	0.000191	0.00224	CcSEcCtD
Dorzolamide—Decreased appetite—Vincristine—colon cancer	0.00019	0.00224	CcSEcCtD
Dorzolamide—Dyspnoea—Irinotecan—colon cancer	0.00019	0.00223	CcSEcCtD
Dorzolamide—Erythema multiforme—Capecitabine—colon cancer	0.00019	0.00223	CcSEcCtD
Dorzolamide—Somnolence—Irinotecan—colon cancer	0.000189	0.00223	CcSEcCtD
Dorzolamide—Fatigue—Vincristine—colon cancer	0.000189	0.00222	CcSEcCtD
Dorzolamide—CA14—Metabolism—CHST5—colon cancer	0.000188	0.00152	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—ODC1—colon cancer	0.000188	0.00152	CbGpPWpGaD
Dorzolamide—Dyspepsia—Irinotecan—colon cancer	0.000187	0.00221	CcSEcCtD
Dorzolamide—Tinnitus—Capecitabine—colon cancer	0.000187	0.0022	CcSEcCtD
Dorzolamide—Pain—Vincristine—colon cancer	0.000187	0.0022	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000186	0.00219	CcSEcCtD
Dorzolamide—Decreased appetite—Irinotecan—colon cancer	0.000185	0.00218	CcSEcCtD
Dorzolamide—Insomnia—Fluorouracil—colon cancer	0.000184	0.00217	CcSEcCtD
Dorzolamide—Fatigue—Irinotecan—colon cancer	0.000184	0.00216	CcSEcCtD
Dorzolamide—Paraesthesia—Fluorouracil—colon cancer	0.000183	0.00216	CcSEcCtD
Dorzolamide—CA5A—Metabolism—CHST5—colon cancer	0.000183	0.00148	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—CHST5—colon cancer	0.000183	0.00148	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—ODC1—colon cancer	0.000183	0.00148	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—ODC1—colon cancer	0.000183	0.00148	CbGpPWpGaD
Dorzolamide—Pain—Irinotecan—colon cancer	0.000182	0.00214	CcSEcCtD
Dorzolamide—Dyspnoea—Fluorouracil—colon cancer	0.000182	0.00214	CcSEcCtD
Dorzolamide—Somnolence—Fluorouracil—colon cancer	0.000181	0.00213	CcSEcCtD
Dorzolamide—Dyspepsia—Fluorouracil—colon cancer	0.00018	0.00211	CcSEcCtD
Dorzolamide—Arrhythmia—Capecitabine—colon cancer	0.000179	0.00211	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Vincristine—colon cancer	0.000179	0.0021	CcSEcCtD
Dorzolamide—Decreased appetite—Fluorouracil—colon cancer	0.000177	0.00209	CcSEcCtD
Dorzolamide—Alopecia—Capecitabine—colon cancer	0.000177	0.00209	CcSEcCtD
Dorzolamide—Feeling abnormal—Irinotecan—colon cancer	0.000175	0.00207	CcSEcCtD
Dorzolamide—Erythema—Capecitabine—colon cancer	0.000175	0.00206	CcSEcCtD
Dorzolamide—Dysuria—Methotrexate—colon cancer	0.000174	0.00205	CcSEcCtD
Dorzolamide—Pain—Fluorouracil—colon cancer	0.000174	0.00205	CcSEcCtD
Dorzolamide—CA1—C-MYB transcription factor network—PTGS2—colon cancer	0.000174	0.00141	CbGpPWpGaD
Dorzolamide—Gastrointestinal pain—Irinotecan—colon cancer	0.000174	0.00205	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Methotrexate—colon cancer	0.000173	0.00204	CcSEcCtD
Dorzolamide—Body temperature increased—Vincristine—colon cancer	0.000173	0.00203	CcSEcCtD
Dorzolamide—Abdominal pain—Vincristine—colon cancer	0.000173	0.00203	CcSEcCtD
Dorzolamide—Erectile dysfunction—Methotrexate—colon cancer	0.000172	0.00202	CcSEcCtD
Dorzolamide—Dysgeusia—Capecitabine—colon cancer	0.000171	0.00201	CcSEcCtD
Dorzolamide—CA5B—Metabolism—ODC1—colon cancer	0.000171	0.00138	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—ODC1—colon cancer	0.000171	0.00138	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—CHST5—colon cancer	0.000171	0.00138	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—CHST5—colon cancer	0.000171	0.00138	CbGpPWpGaD
Dorzolamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000169	0.00137	CbGpPWpGaD
Dorzolamide—Back pain—Capecitabine—colon cancer	0.000169	0.00199	CcSEcCtD
Dorzolamide—CA9—Metabolism—CA7—colon cancer	0.000168	0.00136	CbGpPWpGaD
Dorzolamide—Body temperature increased—Irinotecan—colon cancer	0.000168	0.00198	CcSEcCtD
Dorzolamide—Abdominal pain—Irinotecan—colon cancer	0.000168	0.00198	CcSEcCtD
Dorzolamide—Feeling abnormal—Fluorouracil—colon cancer	0.000168	0.00198	CcSEcCtD
Dorzolamide—CYP3A4—liver—colon cancer	0.000167	0.00837	CbGeAlD
Dorzolamide—Depression—Methotrexate—colon cancer	0.000166	0.00195	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000165	0.00194	CcSEcCtD
Dorzolamide—Vision blurred—Capecitabine—colon cancer	0.000165	0.00194	CcSEcCtD
Dorzolamide—Urticaria—Fluorouracil—colon cancer	0.000162	0.00191	CcSEcCtD
Dorzolamide—Conjunctivitis—Methotrexate—colon cancer	0.000162	0.0019	CcSEcCtD
Dorzolamide—Body temperature increased—Fluorouracil—colon cancer	0.000161	0.0019	CcSEcCtD
Dorzolamide—Hypersensitivity—Vincristine—colon cancer	0.000161	0.0019	CcSEcCtD
Dorzolamide—Sweating—Methotrexate—colon cancer	0.000159	0.00188	CcSEcCtD
Dorzolamide—CA12—Metabolism—ODC1—colon cancer	0.000158	0.00128	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—CHST5—colon cancer	0.000158	0.00128	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—CCND1—colon cancer	0.000157	0.00127	CbGpPWpGaD
Dorzolamide—Epistaxis—Methotrexate—colon cancer	0.000157	0.00185	CcSEcCtD
Dorzolamide—Vertigo—Capecitabine—colon cancer	0.000157	0.00185	CcSEcCtD
Dorzolamide—Hypersensitivity—Irinotecan—colon cancer	0.000157	0.00185	CcSEcCtD
Dorzolamide—Asthenia—Vincristine—colon cancer	0.000157	0.00185	CcSEcCtD
Dorzolamide—Syncope—Capecitabine—colon cancer	0.000157	0.00184	CcSEcCtD
Dorzolamide—Agranulocytosis—Methotrexate—colon cancer	0.000155	0.00183	CcSEcCtD
Dorzolamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000155	0.00125	CbGpPWpGaD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000154	0.00125	CbGpPWpGaD
Dorzolamide—Palpitations—Capecitabine—colon cancer	0.000154	0.00182	CcSEcCtD
Dorzolamide—Loss of consciousness—Capecitabine—colon cancer	0.000154	0.00181	CcSEcCtD
Dorzolamide—Asthenia—Irinotecan—colon cancer	0.000153	0.0018	CcSEcCtD
Dorzolamide—Cough—Capecitabine—colon cancer	0.000152	0.00179	CcSEcCtD
Dorzolamide—CA1—C-MYB transcription factor network—CDKN1A—colon cancer	0.000152	0.00123	CbGpPWpGaD
Dorzolamide—Hypertension—Capecitabine—colon cancer	0.000151	0.00177	CcSEcCtD
Dorzolamide—Hypersensitivity—Fluorouracil—colon cancer	0.00015	0.00177	CcSEcCtD
Dorzolamide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.00015	0.00122	CbGpPWpGaD
Dorzolamide—Diarrhoea—Vincristine—colon cancer	0.00015	0.00176	CcSEcCtD
Dorzolamide—Arthralgia—Capecitabine—colon cancer	0.000149	0.00175	CcSEcCtD
Dorzolamide—Chest pain—Capecitabine—colon cancer	0.000149	0.00175	CcSEcCtD
Dorzolamide—Pharyngitis—Methotrexate—colon cancer	0.000148	0.00174	CcSEcCtD
Dorzolamide—Anxiety—Capecitabine—colon cancer	0.000148	0.00174	CcSEcCtD
Dorzolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000147	0.00119	CbGpPWpGaD
Dorzolamide—Discomfort—Capecitabine—colon cancer	0.000147	0.00173	CcSEcCtD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000146	0.00118	CbGpPWpGaD
Dorzolamide—Diarrhoea—Irinotecan—colon cancer	0.000146	0.00171	CcSEcCtD
Dorzolamide—Dry mouth—Capecitabine—colon cancer	0.000145	0.00171	CcSEcCtD
Dorzolamide—CA1—C-MYB transcription factor network—EP300—colon cancer	0.000145	0.00117	CbGpPWpGaD
Dorzolamide—Dizziness—Vincristine—colon cancer	0.000145	0.0017	CcSEcCtD
Dorzolamide—Pruritus—Fluorouracil—colon cancer	0.000144	0.0017	CcSEcCtD
Dorzolamide—Visual impairment—Methotrexate—colon cancer	0.000144	0.00169	CcSEcCtD
Dorzolamide—Confusional state—Capecitabine—colon cancer	0.000144	0.00169	CcSEcCtD
Dorzolamide—Oedema—Capecitabine—colon cancer	0.000143	0.00168	CcSEcCtD
Dorzolamide—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000142	0.00115	CbGpPWpGaD
Dorzolamide—Erythema multiforme—Methotrexate—colon cancer	0.000141	0.00166	CcSEcCtD
Dorzolamide—Dizziness—Irinotecan—colon cancer	0.000141	0.00166	CcSEcCtD
Dorzolamide—Shock—Capecitabine—colon cancer	0.00014	0.00165	CcSEcCtD
Dorzolamide—Diarrhoea—Fluorouracil—colon cancer	0.00014	0.00164	CcSEcCtD
Dorzolamide—Tinnitus—Methotrexate—colon cancer	0.000139	0.00164	CcSEcCtD
Dorzolamide—Vomiting—Vincristine—colon cancer	0.000139	0.00164	CcSEcCtD
Dorzolamide—Rash—Vincristine—colon cancer	0.000138	0.00162	CcSEcCtD
Dorzolamide—Hyperhidrosis—Capecitabine—colon cancer	0.000138	0.00162	CcSEcCtD
Dorzolamide—Dermatitis—Vincristine—colon cancer	0.000138	0.00162	CcSEcCtD
Dorzolamide—Headache—Vincristine—colon cancer	0.000137	0.00161	CcSEcCtD
Dorzolamide—Anorexia—Capecitabine—colon cancer	0.000136	0.0016	CcSEcCtD
Dorzolamide—CA1—C-MYB transcription factor network—NRAS—colon cancer	0.000136	0.0011	CbGpPWpGaD
Dorzolamide—Vomiting—Irinotecan—colon cancer	0.000135	0.00159	CcSEcCtD
Dorzolamide—Dizziness—Fluorouracil—colon cancer	0.000135	0.00159	CcSEcCtD
Dorzolamide—Rash—Irinotecan—colon cancer	0.000134	0.00158	CcSEcCtD
Dorzolamide—Dermatitis—Irinotecan—colon cancer	0.000134	0.00158	CcSEcCtD
Dorzolamide—Headache—Irinotecan—colon cancer	0.000133	0.00157	CcSEcCtD
Dorzolamide—Hypotension—Capecitabine—colon cancer	0.000133	0.00157	CcSEcCtD
Dorzolamide—Alopecia—Methotrexate—colon cancer	0.000132	0.00155	CcSEcCtD
Dorzolamide—Erythema—Methotrexate—colon cancer	0.00013	0.00153	CcSEcCtD
Dorzolamide—Nausea—Vincristine—colon cancer	0.00013	0.00153	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00013	0.00153	CcSEcCtD
Dorzolamide—Vomiting—Fluorouracil—colon cancer	0.00013	0.00153	CcSEcCtD
Dorzolamide—Insomnia—Capecitabine—colon cancer	0.000129	0.00152	CcSEcCtD
Dorzolamide—Rash—Fluorouracil—colon cancer	0.000129	0.00151	CcSEcCtD
Dorzolamide—Dermatitis—Fluorouracil—colon cancer	0.000128	0.00151	CcSEcCtD
Dorzolamide—Paraesthesia—Capecitabine—colon cancer	0.000128	0.00151	CcSEcCtD
Dorzolamide—Headache—Fluorouracil—colon cancer	0.000128	0.0015	CcSEcCtD
Dorzolamide—Dysgeusia—Methotrexate—colon cancer	0.000127	0.0015	CcSEcCtD
Dorzolamide—Dyspnoea—Capecitabine—colon cancer	0.000127	0.0015	CcSEcCtD
Dorzolamide—Nausea—Irinotecan—colon cancer	0.000126	0.00149	CcSEcCtD
Dorzolamide—CA4—Metabolism—CHST5—colon cancer	0.000126	0.00102	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—ODC1—colon cancer	0.000126	0.00102	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—MYC—colon cancer	0.000126	0.00102	CbGpPWpGaD
Dorzolamide—Back pain—Methotrexate—colon cancer	0.000126	0.00148	CcSEcCtD
Dorzolamide—Dyspepsia—Capecitabine—colon cancer	0.000125	0.00148	CcSEcCtD
Dorzolamide—Decreased appetite—Capecitabine—colon cancer	0.000124	0.00146	CcSEcCtD
Dorzolamide—Fatigue—Capecitabine—colon cancer	0.000123	0.00145	CcSEcCtD
Dorzolamide—Vision blurred—Methotrexate—colon cancer	0.000123	0.00144	CcSEcCtD
Dorzolamide—Pain—Capecitabine—colon cancer	0.000122	0.00143	CcSEcCtD
Dorzolamide—Nausea—Fluorouracil—colon cancer	0.000121	0.00143	CcSEcCtD
Dorzolamide—CA2—Metabolism—CHST5—colon cancer	0.000121	0.00098	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—ODC1—colon cancer	0.000121	0.00098	CbGpPWpGaD
Dorzolamide—Feeling abnormal—Capecitabine—colon cancer	0.000117	0.00138	CcSEcCtD
Dorzolamide—Vertigo—Methotrexate—colon cancer	0.000117	0.00137	CcSEcCtD
Dorzolamide—CA1—C-MYB transcription factor network—KRAS—colon cancer	0.000117	0.000944	CbGpPWpGaD
Dorzolamide—Gastrointestinal pain—Capecitabine—colon cancer	0.000117	0.00137	CcSEcCtD
Dorzolamide—CA1—Metabolism—ODC1—colon cancer	0.000116	0.000939	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—CHST5—colon cancer	0.000116	0.000939	CbGpPWpGaD
Dorzolamide—Cough—Methotrexate—colon cancer	0.000113	0.00133	CcSEcCtD
Dorzolamide—Urticaria—Capecitabine—colon cancer	0.000113	0.00133	CcSEcCtD
Dorzolamide—Abdominal pain—Capecitabine—colon cancer	0.000113	0.00133	CcSEcCtD
Dorzolamide—Body temperature increased—Capecitabine—colon cancer	0.000113	0.00133	CcSEcCtD
Dorzolamide—Arthralgia—Methotrexate—colon cancer	0.000111	0.0013	CcSEcCtD
Dorzolamide—Chest pain—Methotrexate—colon cancer	0.000111	0.0013	CcSEcCtD
Dorzolamide—Discomfort—Methotrexate—colon cancer	0.000109	0.00129	CcSEcCtD
Dorzolamide—Confusional state—Methotrexate—colon cancer	0.000107	0.00126	CcSEcCtD
Dorzolamide—Anaphylactic shock—Methotrexate—colon cancer	0.000106	0.00125	CcSEcCtD
Dorzolamide—Hypersensitivity—Capecitabine—colon cancer	0.000105	0.00124	CcSEcCtD
Dorzolamide—Hyperhidrosis—Methotrexate—colon cancer	0.000103	0.00121	CcSEcCtD
Dorzolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000102	0.000829	CbGpPWpGaD
Dorzolamide—Asthenia—Capecitabine—colon cancer	0.000102	0.0012	CcSEcCtD
Dorzolamide—CA9—Metabolism—ODC1—colon cancer	0.000102	0.000826	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—CHST5—colon cancer	0.000102	0.000826	CbGpPWpGaD
Dorzolamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000102	0.000825	CbGpPWpGaD
Dorzolamide—Anorexia—Methotrexate—colon cancer	0.000101	0.00119	CcSEcCtD
Dorzolamide—Pruritus—Capecitabine—colon cancer	0.000101	0.00119	CcSEcCtD
Dorzolamide—CA1—C-MYB transcription factor network—HRAS—colon cancer	9.92e-05	0.000802	CbGpPWpGaD
Dorzolamide—Hypotension—Methotrexate—colon cancer	9.91e-05	0.00117	CcSEcCtD
Dorzolamide—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	9.91e-05	0.000802	CbGpPWpGaD
Dorzolamide—Diarrhoea—Capecitabine—colon cancer	9.75e-05	0.00115	CcSEcCtD
Dorzolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	9.71e-05	0.000786	CbGpPWpGaD
Dorzolamide—Musculoskeletal discomfort—Methotrexate—colon cancer	9.67e-05	0.00114	CcSEcCtD
Dorzolamide—Insomnia—Methotrexate—colon cancer	9.6e-05	0.00113	CcSEcCtD
Dorzolamide—Paraesthesia—Methotrexate—colon cancer	9.53e-05	0.00112	CcSEcCtD
Dorzolamide—Dyspnoea—Methotrexate—colon cancer	9.46e-05	0.00111	CcSEcCtD
Dorzolamide—Somnolence—Methotrexate—colon cancer	9.43e-05	0.00111	CcSEcCtD
Dorzolamide—Dizziness—Capecitabine—colon cancer	9.43e-05	0.00111	CcSEcCtD
Dorzolamide—Dyspepsia—Methotrexate—colon cancer	9.34e-05	0.0011	CcSEcCtD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—AKT1—colon cancer	9.34e-05	0.000755	CbGpPWpGaD
Dorzolamide—Decreased appetite—Methotrexate—colon cancer	9.22e-05	0.00109	CcSEcCtD
Dorzolamide—Fatigue—Methotrexate—colon cancer	9.15e-05	0.00108	CcSEcCtD
Dorzolamide—Pain—Methotrexate—colon cancer	9.07e-05	0.00107	CcSEcCtD
Dorzolamide—Vomiting—Capecitabine—colon cancer	9.06e-05	0.00107	CcSEcCtD
Dorzolamide—Rash—Capecitabine—colon cancer	8.99e-05	0.00106	CcSEcCtD
Dorzolamide—Dermatitis—Capecitabine—colon cancer	8.98e-05	0.00106	CcSEcCtD
Dorzolamide—Headache—Capecitabine—colon cancer	8.93e-05	0.00105	CcSEcCtD
Dorzolamide—Feeling abnormal—Methotrexate—colon cancer	8.74e-05	0.00103	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Methotrexate—colon cancer	8.68e-05	0.00102	CcSEcCtD
Dorzolamide—Nausea—Capecitabine—colon cancer	8.47e-05	0.000996	CcSEcCtD
Dorzolamide—Urticaria—Methotrexate—colon cancer	8.43e-05	0.000992	CcSEcCtD
Dorzolamide—Abdominal pain—Methotrexate—colon cancer	8.39e-05	0.000987	CcSEcCtD
Dorzolamide—Body temperature increased—Methotrexate—colon cancer	8.39e-05	0.000987	CcSEcCtD
Dorzolamide—Hypersensitivity—Methotrexate—colon cancer	7.82e-05	0.00092	CcSEcCtD
Dorzolamide—Asthenia—Methotrexate—colon cancer	7.61e-05	0.000896	CcSEcCtD
Dorzolamide—Pruritus—Methotrexate—colon cancer	7.51e-05	0.000883	CcSEcCtD
Dorzolamide—Diarrhoea—Methotrexate—colon cancer	7.26e-05	0.000854	CcSEcCtD
Dorzolamide—Dizziness—Methotrexate—colon cancer	7.02e-05	0.000826	CcSEcCtD
Dorzolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	6.76e-05	0.000547	CbGpPWpGaD
Dorzolamide—Vomiting—Methotrexate—colon cancer	6.75e-05	0.000794	CcSEcCtD
Dorzolamide—Rash—Methotrexate—colon cancer	6.69e-05	0.000787	CcSEcCtD
Dorzolamide—Dermatitis—Methotrexate—colon cancer	6.68e-05	0.000786	CcSEcCtD
Dorzolamide—Headache—Methotrexate—colon cancer	6.65e-05	0.000782	CcSEcCtD
Dorzolamide—Nausea—Methotrexate—colon cancer	6.3e-05	0.000742	CcSEcCtD
Dorzolamide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	5.92e-05	0.000479	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—CDKN1A—colon cancer	5.36e-05	0.000433	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—EP300—colon cancer	5.1e-05	0.000412	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—ABCB1—colon cancer	4.97e-05	0.000402	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—TYMS—colon cancer	4.88e-05	0.000395	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—ABCB1—colon cancer	4.84e-05	0.000391	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—ABCB1—colon cancer	4.84e-05	0.000391	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—VEGFA—colon cancer	4.83e-05	0.00039	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—TYMS—colon cancer	4.75e-05	0.000384	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—TYMS—colon cancer	4.75e-05	0.000384	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—ABCB1—colon cancer	4.52e-05	0.000365	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—ABCB1—colon cancer	4.52e-05	0.000365	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—TYMS—colon cancer	4.44e-05	0.000359	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—TYMS—colon cancer	4.44e-05	0.000359	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—CA7—colon cancer	4.3e-05	0.000348	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—ABCB1—colon cancer	4.19e-05	0.000339	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—TYMS—colon cancer	4.11e-05	0.000333	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—TP53—colon cancer	3.65e-05	0.000295	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PPARG—colon cancer	3.46e-05	0.000279	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PPARG—colon cancer	3.37e-05	0.000272	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PPARG—colon cancer	3.37e-05	0.000272	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—ABCB1—colon cancer	3.34e-05	0.00027	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—TYMS—colon cancer	3.28e-05	0.000265	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—ABCB1—colon cancer	3.2e-05	0.000259	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PPARG—colon cancer	3.14e-05	0.000254	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PPARG—colon cancer	3.14e-05	0.000254	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—TYMS—colon cancer	3.14e-05	0.000254	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—ABCB1—colon cancer	3.07e-05	0.000248	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—TYMS—colon cancer	3.01e-05	0.000244	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PPARG—colon cancer	2.91e-05	0.000236	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—CA7—colon cancer	2.84e-05	0.000229	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PTGS2—colon cancer	2.72e-05	0.00022	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—ABCB1—colon cancer	2.7e-05	0.000218	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—TYMS—colon cancer	2.65e-05	0.000214	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PTGS2—colon cancer	2.65e-05	0.000214	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PTGS2—colon cancer	2.65e-05	0.000214	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—ODC1—colon cancer	2.61e-05	0.000211	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—CHST5—colon cancer	2.61e-05	0.000211	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PTGS2—colon cancer	2.47e-05	0.0002	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PTGS2—colon cancer	2.47e-05	0.0002	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PPARG—colon cancer	2.32e-05	0.000188	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PTGS2—colon cancer	2.29e-05	0.000185	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—EP300—colon cancer	2.26e-05	0.000183	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PPARG—colon cancer	2.23e-05	0.00018	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—EP300—colon cancer	2.2e-05	0.000178	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—EP300—colon cancer	2.2e-05	0.000178	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PPARG—colon cancer	2.13e-05	0.000173	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—EP300—colon cancer	2.06e-05	0.000166	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—EP300—colon cancer	2.06e-05	0.000166	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—EP300—colon cancer	1.91e-05	0.000154	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PPARG—colon cancer	1.88e-05	0.000152	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PTGS2—colon cancer	1.83e-05	0.000148	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PTGS2—colon cancer	1.75e-05	0.000142	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—ODC1—colon cancer	1.72e-05	0.000139	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—CHST5—colon cancer	1.72e-05	0.000139	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PTGS2—colon cancer	1.68e-05	0.000136	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PIK3CA—colon cancer	1.67e-05	0.000135	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PIK3CA—colon cancer	1.63e-05	0.000132	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PIK3CA—colon cancer	1.63e-05	0.000132	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PIK3CA—colon cancer	1.52e-05	0.000123	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PIK3CA—colon cancer	1.52e-05	0.000123	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—EP300—colon cancer	1.52e-05	0.000123	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PTGS2—colon cancer	1.48e-05	0.000119	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—EP300—colon cancer	1.46e-05	0.000118	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PIK3CA—colon cancer	1.41e-05	0.000114	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—EP300—colon cancer	1.4e-05	0.000113	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—AKT1—colon cancer	1.37e-05	0.000111	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—AKT1—colon cancer	1.33e-05	0.000108	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—AKT1—colon cancer	1.33e-05	0.000108	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—AKT1—colon cancer	1.24e-05	0.000101	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—AKT1—colon cancer	1.24e-05	0.000101	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—EP300—colon cancer	1.23e-05	9.93e-05	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—AKT1—colon cancer	1.15e-05	9.31e-05	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PIK3CA—colon cancer	1.12e-05	9.09e-05	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PIK3CA—colon cancer	1.08e-05	8.72e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.08e-05	8.7e-05	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PIK3CA—colon cancer	1.03e-05	8.36e-05	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—AKT1—colon cancer	9.18e-06	7.43e-05	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PIK3CA—colon cancer	9.08e-06	7.35e-05	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—AKT1—colon cancer	8.8e-06	7.12e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.46e-06	6.84e-05	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—AKT1—colon cancer	8.44e-06	6.83e-05	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—AKT1—colon cancer	7.42e-06	6e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.04e-06	5.69e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—ABCB1—colon cancer	6.89e-06	5.57e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—TYMS—colon cancer	6.76e-06	5.47e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.21e-06	4.21e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PPARG—colon cancer	4.79e-06	3.87e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—ABCB1—colon cancer	4.54e-06	3.67e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—TYMS—colon cancer	4.46e-06	3.61e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PTGS2—colon cancer	3.77e-06	3.05e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PPARG—colon cancer	3.16e-06	2.56e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—EP300—colon cancer	3.13e-06	2.54e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PTGS2—colon cancer	2.49e-06	2.01e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PIK3CA—colon cancer	2.32e-06	1.88e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—EP300—colon cancer	2.07e-06	1.67e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—AKT1—colon cancer	1.89e-06	1.53e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PIK3CA—colon cancer	1.53e-06	1.24e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—AKT1—colon cancer	1.25e-06	1.01e-05	CbGpPWpGaD
